Tiziana to host investor call to discuss exclusive license agreement to evaluate foralumab, a novel, fully human anti-cd3 monoclonal antibody, in conjunction with allogeneic car t candidates for cancer treatment

New york and london, sept. 07, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils) ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, will host a conference call and audio webcast on wednesday, september 8, at 4:15 p.m. et to discuss its recently announced exclusive license agreement to evaluate foralumab, the company's novel, fully human anti-cd3 monoclonal antibody, in conjunction with allogenic car t candidates for cancer treatment.
TLSA Ratings Summary
TLSA Quant Ranking